The PDAC stroma has been demonstrated to not only promote tumour progression but to also dampen the delivery of antitumour regimens [24–26], even increasing the number of immunosuppressive cells and inactivating cytotoxic CD8+ T cells [27, 28]. The gene discussed is CD8A; the disease is neoplasm.